{"id":"decitabine-plus-haag-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL1201129","moleculeType":"Small molecule","molecularWeight":"228.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Decitabine is a hypomethylating agent that inhibits DNA methyltransferase, leading to reactivation of silenced tumor suppressor genes and differentiation of myeloid blasts. The HAAG regimen provides intensive chemotherapy with cytarabine, aclarubicin, and amsacrine to enhance cytotoxic effects. This combination approach targets both epigenetic mechanisms and direct cell kill in acute myeloid leukemia.","oneSentence":"Decitabine plus HAAG (low-dose cytarabine, aclarubicin, amsacrine, and G-CSF) combines DNA methyltransferase inhibition with intensive chemotherapy to induce differentiation and apoptosis in leukemic cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:26.920Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), particularly in elderly or unfit patients"}]},"trialDetails":[{"nctId":"NCT04446130","phase":"PHASE3","title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":"Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia","enrollment":100},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":162},{"nctId":"NCT04083911","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Decitabine plus HAAG regimen","genericName":"Decitabine plus HAAG regimen","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Decitabine plus HAAG (low-dose cytarabine, aclarubicin, amsacrine, and G-CSF) combines DNA methyltransferase inhibition with intensive chemotherapy to induce differentiation and apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), particularly in elderly or unfit patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}